Mid-Year Peptide Stack Review: Reassessing Your Research Protocol for H2 2026

A framework for mid-year research protocol review — how to assess what's working in your peptide and supplement stack, what biomarkers to check at 6 months, which compounds to cycle off for H2, what new research to incorporate, and how to design an optimized second-half protocol.

TL;DR

• Mid-year is the ideal time for a protocol reassessment with a full biomarker panel
• Identify what's working (objective improvement), what's uncertain (subjective only), what to cycle off
• Compounds used 12+ weeks continuously should generally cycle off; foundational supplements continue
• Design H2 protocol with fresh objectives, new cycling schedules, and updated compounds based on new research
• Review security of compound sourcing and COA documentation for anything continuing

Disclaimer: For educational and research purposes only — not medical advice.

A research protocol that remains static is not research — it's habit. Effective peptide and supplement research requires periodic, systematic reassessment to evaluate what's actually working, correct protocols that aren't producing expected results, cycle off compounds that have run their course, and incorporate new evidence that has emerged since the protocol began.

The Mid-Year Review Framework

Step 1: Audit Your Current Stack

Before you can optimize, document what you're actually doing — including doses, timing, consistency, and any deviations from the intended protocol.

Audit questions:

• Which compounds have you taken consistently (>80% of days)? Which inconsistently?
• Have doses changed from the original protocol? Why?
• Which compounds have been used continuously since January (may need cycling)?
• Are there any compounds you added without planning (reactive, uncontrolled)?
• What was the original hypothesis or goal for each compound?

Step 2: Objective Assessment — Biomarkers

Subjective perception of "feeling better" is not research. The mid-year review should anchor to objective measurement wherever possible.

Priority biomarker panel for H1 → H2 transition:

Interpret in context: Compare to your baseline (drawn before starting H1 protocol), not just to population reference ranges. A testosterone change of 200 ng/dL may be more meaningful than an absolute value.

Step 3: Performance and Body Composition Assessment

For researchers focused on physical performance:

Step 4: Cognitive Assessment

For researchers focused on cognitive optimization:

• Repeat the same cognitive battery used at baseline (Cambridge Brain Sciences, BrainHQ, or equivalent)
• Compare absolute scores and percentile rankings to H1 start
• Self-report journals on focus quality, memory recall, mood stability

Step 5: Cycling Decisions

Based on your duration assessment:

Compounds to cycle off for 4-8 weeks entering H2:

• GH peptides (if used >12 weeks continuously)
• Ibutamoren/MK-677 (if used >16 weeks continuously)
• Racetams
• Strong adaptogens (Ashwagandha, Rhodiola)
• Semax/Selank (if used >6 weeks continuously)
• Any dopamine agonists used for >8 weeks

Compounds that can continue without cycling:

• Omega-3 fatty acids (foundational, no receptor adaptation)
• Magnesium Glycinate
• Zinc
• Vitamin D3+K2
• Creatine monohydrate
• Collagen peptides
• Lion's Mane (continuous evidence; modest tolerance profile)
• NAD+ precursors (NMN/NR — continuous use appears appropriate)

Step 6: H2 Protocol Design

With H1 data in hand, design H2 with:

Objectives reset: What are the primary research goals for July-December?

• Body composition phase (cut vs. bulk vs. recomp)?
• Performance optimization cycle?
• Longevity/anti-aging focus?
• Cognitive enhancement priority?

Compound selection: Based on H1 biomarker data, select compounds addressing identified gaps:

• Low IGF-1 → prioritize GH peptide protocol in H2
• High cortisol → adapt → prioritize cortisol optimization (adaptogens, sleep)
• Poor sleep HRV → add sleep optimization layer
• Cognitive gaps → add or intensify nootropic layer

Updated cycle plan: Schedule specific cycling periods in advance (don't rely on "I'll cycle when I feel like it"):

• Weeks 1-8: Protocol A
• Weeks 9-10: Partial cycle off (continue foundations)
• Weeks 11-18: Protocol B with refreshed compounds

Sourcing Audit for H2

Mid-year is also a good time to review research compound sourcing:

• Has your supplier provided updated COAs with lot-specific testing?
• Have any compounds been ordered from new/untested suppliers?
• Are independent testing (Janoshik or equivalent) results on file for new sources?
• Has any batch produced unexpected effects that might indicate quality issues?

Frequently Asked Questions

Q: What if my mid-year biomarkers show unexpected changes from the H1 protocol? A: Unexpected changes require investigation before continuing. Red flags that warrant protocol pause: significant liver enzyme elevation (ALT/AST >2x upper normal), significant testosterone suppression beyond expected range, unexplained lipid changes, or new symptoms correlated with protocol changes. Work backwards to identify which compound(s) are most likely responsible — eliminate them from the H2 protocol and retest after 6-8 weeks. This is research — unexpected findings are data, not failures.

Q: How do I know if a compound is actually working vs. placebo effect? A: This is the fundamental challenge of n=1 research without a control arm. Strategies to improve confidence: (1) Objective biomarker changes (IGF-1 elevation after GH peptides is objective, not placebo); (2) Dose-response testing — if the effect is real, reducing dose should reduce effect; (3) Single-compound addition — add one compound at a time rather than stacking, so any change can be attributed; (4) Blinded self-testing — have someone else measure outcomes when possible; (5) Objective performance testing — cognitive batteries and physical performance tests are less susceptible to expectation bias than subjective ratings.

Use the Stack Builder Calculator → /calculators/stack

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions